Patents Assigned to Merck
  • Stable formulations of testosterone undecanoate
    Patent number: 9925200
    Abstract: The present invention is directed to stable pharmaceutical formulations. More specifically, the present invention is directed to stable pharmaceutical formulations of testosterone undecanoate.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme B.V.
    Inventor: Gerritdina G. Schoonus-Gerritsma
  • Liquid crystal medium
    Patent number: 9926490
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerizable compound, one or more compounds of formula Q, and one or more compounds of formula AN1 to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: March 27, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dong-Mee Song, Eun-Kyu Lee, Seung-Eun Lee
  • Pyridyl piperidines
    Patent number: 9926319
    Abstract: The invention provides novel substituted pyridyl piperidine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 27, 2018
    Assignees: MERCK PATENT GMBH, Cancer Research Technology Limited
    Inventors: Kai Schiemann, Frank Stieber, Michel Calderini, Julian Blagg, Aurelie Mallinger, Dennis Waalboer, Christian Rink, Simon Ross Crumpler
  • Method for treating cancer
    Patent number: 9925192
    Abstract: A method for the treatment of cancer by administering a therapeutically effective amount of a cyclin-dependent kinase (CDK) inhibitor with a therapeutically effective amount of a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor (“B Cell CLL/Lymphoma 2”, or “BCL-2”). Administration of the CDK inhibitor and BCL-2 inhibitor can be simultaneous, successive or separate.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Strack, Robert Booher
  • Cladribine regimen for treating multiple sclerosis
    Patent number: 9925151
    Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: March 27, 2018
    Assignee: MERCK SERONO SA
    Inventors: H. James Brentzel, Jr., Maria Lopez-Bresnahan, Nazih Ammoury
  • Pegylated interleukin-10
    Patent number: 9925245
    Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Seoju Lee, David C. Wylie, Susan V. Cannon-Carlson
  • A COLOR CONVERSION FILM, AND OPTICAL DEVICES
    Publication number: 20180081096
    Abstract: The present invention relates to a color conversion film and to a use of the color conversion film in an optical device. The color conversion film comprises a red sub color area which comprises nanosized 1st and 2nd red color converting material and a green sub color area which comprises nanosized 1st and 2nd green color converting material. The invention further relates to an optical device comprising the color conversion film, a light switching element, and a color filter. The invention also relates to method for preparing the color conversion film, and method for preparing the optical device.
    Type: Application
    Filed: February 18, 2016
    Publication date: March 22, 2018
    Applicant: MERCK PATENT GMBH
    Inventor: Eddy CLAES
  • PROCESS OF MAKING AND USING PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS
    Publication number: 20180078546
    Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 22, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sydney O. Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
  • FACTOR XIa INHIBITORS
    Publication number: 20180079743
    Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Eric Mertz, Scott D. Edmondson, Sung-Sau So, Wanying Sun, Weiguo Liu, Santhosh F. Neelamkavil, Ying-Duo Gao, Alan Hruza, Yi Zang, Amjad Ali, Rudrajit Mal, Jiafang He, Rongze Kuang, Heping Wu, Anthony K. Ogawa, Andrew F. Nolting
  • IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE
    Publication number: 20180080938
    Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 22, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Marisa Dolled-Filhart, Kenneth Emancipator, Frank Lynch, Robert H. Pierce, Dianna Wu
  • BTK INHIBITORS
    Publication number: 20180079752
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Application
    Filed: May 31, 2016
    Publication date: March 22, 2018
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.
    Inventors: ADRIANUS PETRUS ANTONIUS DE MAN, RONALD KIM, JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, THIERRY FISCHMANN, DEODIAL Guy GUIADEEN, ILSE HENDRICA MARIA POLS-DE ROOIJ, SHILAN LIU, HAO WU
  • Compounds and liquid-crystalline medium
    Patent number: 9920248
    Abstract: The invention relates to compounds of the formula I, and to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises one or more compounds of formula I, defined herein, for use in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, FFS or IPS effect, and to the use of the compounds of the formula I for the stabilization of a liquid-crystalline medium which comprises one or more compounds of the formula II and one or more compounds of the formulae III-1 to III-4, defined herein.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 20, 2018
    Assignee: Merck Patent GmbH
    Inventors: Mark Goebel, Rocco Fortte, Detlef Pauluth
  • Method for producing organic electronic devices with bank structures, bank structures and electronic devices produced therewith
    Patent number: 9923035
    Abstract: The present invention relates to a process for producing an organic electronic device, wherein a layer is selectively swelled with a swelling solvent so as to form bank structures allowing the deposition of the semiconductor material in a specific and well-defined area. The present invention further relates to bank structures, organic electronic devices and products or assemblies produced by said process.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: March 20, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Rashmi Bhintade, Li Wei Tan, Tomas Backlund
  • Methyl oxazole orexin receptor antagonists
    Patent number: 9920038
    Abstract: The present invention is directed to methyloxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 20, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Organic ionic functional materials
    Patent number: 9923152
    Abstract: The present invention relates to a novel non-polymeric organic ionic compound comprising one ion having a functional organic group, such as a matrix group, a hole injection group, a hole transport group, an electron injection group and an electron transport group, and comprising another ion preferably being so small that it may act as a mobile ion in films containing the organic ionic compound. Furthermore, the present invention relates to a composition containing the novel organic ionic compound and another functional compound. The novel organic ionic compound or the composition may be used in organic devices as functional materials, such as matrix materials or for materials charge transport. The resulting organic devices are also object of the present invention.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: March 20, 2018
    Assignee: Merck Patent GmbH
    Inventors: Junyou Pan, Amir Hossain Parham
  • Phosphors
    Patent number: 9920246
    Abstract: The present invention relates to silicate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: March 20, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ralf Petry, Holger Winkler, Thomas Juestel, Matthias Mueller
  • PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES
    Publication number: 20180071412
    Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
    Type: Application
    Filed: October 4, 2017
    Publication date: March 15, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abbas M. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
  • SILICON DIOXIDE NANOPARTICLES AND THE USE THEREOF FOR VACCINATION
    Publication number: 20180071386
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20180072715
    Abstract: Compounds of the formula (I), which are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 15, 2018
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • COMBINATION OF A PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER
    Publication number: 20180071247
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 15, 2018
    Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.
    Inventors: Junji MATSUI, Gursel AKTAN, Vassiliki KARANTZA, RuiRong YUAN, Yasuhiro FUNAHASHI, Erhan BERRAK